Quadsimia, LLC

MelMedtronics Teams With Quadsimia

(Jul. 25, 2012)

Dallas, Texas - New Tinnitus Software Programs Planned

Dr. David W. Holmes, of Melmedtronics, announces a long-term agreement with Quadsimia to develop a series of tinnitus evaluation programs and applications for computers, tablets and phones. According to Holmes, there are approximately 50 million individuals in the U.S. who have tinnitus and more than 135 million in Europe.

Quadsimia is a one of the premier software and application development companies in the world and Melmedtronics has established themselves as one of the most innovative companies, with regard to developing products for tinnitus. Holmes sees great synergy by this teaming arrangement.

The first product will be a revision of Melmedtronics's original Tinnitus Evaluation Program (TEP) software. The new version will allow healthcare providers to evaluate their tinnitus patients in 7-10 minutes. The program will self-generate a Clinical Report, allow providers to document their evaluation and then bill for their services. Holmes expects the first product to launch in October, 2012.

Other products currently in development will follow. There will be a combination of programs for healthcare providers and consumers. Holmes expects that many of the products will be translated for a world-wide market. More information can be found at www.melmedtronics.com.

DAVID W. HOLMES, Ph.D. Board Certified in Audiology - He is a fellow of the American Academy of Audiology. He holds, or has filed, patents for six devices, including his latest ultrasonic tinnitus treatment device called The Inhibitor. For Dr. Holmes' full professional background, visit www.melmedtronics.com.